nor-NOHA acetate
Based on 7 publication(s) in Google Scholar
nor-NOHA acetate is a selective and reversible Arginase inhibitor. nor-NOHA acetate induces Apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA acetate has anti-leukemic activity. nor-NOHA acetate improves liver ischemia-reperfusion injury. nor-NOHA acetate can used in study of tuberculosis, endothelial dysfunction, immunosuppression and metabolism.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.52%
- CAS 番号: 1140844-63-8
- 分子式: C9H20N4O7
- 分子量:296.28
-
保管条件:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-tuberculosis Compound Library
HY-L142
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Amino Acid Metabolism Compound Library
HY-L189
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
MedChemExpress（MCE）の使用を引用している文献 nor-NOHA acetate
More- Cell. 2025 Dec 11;188(25):7291-7308.e23. [Abstract]
- Free Radic Biol Med. 2026 Apr:247:516-527. [Abstract]
- Chin Med. 2026 May 28;21(1):151. [Abstract]
- Front Cell Dev Biol. 2021 Dec 23;9:741911. [Abstract]
- FASEB J. 2025 Sep 30;39(18):e71057. [Abstract]
- Clin Immunol. 2024 Sep 3:110355. [Abstract]
- Res Sq. 2026 May 8:rs.3.rs-9404453. [Abstract]
Customer Validation & Images
-
Flow Cytometry
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
Bio/Physico-chemical Assay
生物活性
Arginase[1]
nor-NOHA (0.1-1 mM, 72 h) acetate induces apoptosis in a dose-dependent manner under hypoxia (1.5% O2) in K562 cells[1].
nor-NOHA (1 mM, 72 h) acetate attenuates hypoxia-mediated resistance towards Imatinib (HY-15463) in K562 or KCL22 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
nor-NOHA (100 mg/kg, i.v., once time) acetate induces a significant reduction of infarct size in male Sprague-Dawley rats[2].
nor-NOHA (100 mg/kg, i.v., once time) acetate increases plasma citrulline and nitrite levels and decreases the ornithine plasma levels in male Sprague-Dawley rats[2].
nor-NOHA (100 mg/kg; intravenous penile vein injection) acetate improves liver I/R injury[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats subjected to ischemia-reperfusion[2]
-
Dosage:100 mg/kg
-
Administration:Intravenous injection (i.v.)
-
Result:Induced a significant reduction of infarct size to 39%.
Did not reduce infarct size when administered together with cPTIO or L-NMMA.
化学情報
-
CAS 番号 1140844-63-8
-
性状 Solid
-
分子量 296.28
-
分子式 C9H20N4O7
-
Color White to off-white
-
SMILES
O=C(O)[C@@H](N)CCNC(NO)=N.CC(O)=O.CC(O)=O
-
別名
Nω-Hydroxy-nor-L-arginine acetate
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Cell
2025 Dec 11;188(25):7291-7308.e23. PMID: 41161316
nor-NOHA acetate purchased from MedChemExpress. Usage Cited in: Cell. 2025 Dec 11;188(25):7291-7308.e23. [Abstract]
Bar plots showing proportions of TNF-α+ T cells in fetal liver whole blood following PMA simulation. T cells were cultured alone (light green) or co-cultured with matched fetal neutrophils (orange) in the presence or absence of ARG1 inhibitor (nonor-NOHA monoacetate; overnight) or L-arginine supplementation, as indicated on the x axis.
-
Free Radic Biol Med
Endothelial Arg2 regulates HIMM-induced mitochondrial hyperfission via affecting arginine metabolism. [Abstract]2026 Apr:247:516-527. PMID: 41720362 -
Chin Med
Licoisoflavone A potentiates oxaliplatin efficacy in colorectal cancer by dual targeting arginine metabolism of tumor microenvironment and cancer cells. [Abstract]2026 May 28;21(1):151. PMID: 42210399 -
Front Cell Dev Biol
mTOR Signaling Regulates the Development and Therapeutic Efficacy of PMN-MDSCs in Acute GVHD. [Abstract]2021 Dec 23;9:741911. PMID: 35004668
nor-NOHA acetate purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2021 Dec 23;9:741911. [Abstract]
nor-NOHA monoacetate (nor-NOHA) efficiently reduced immunosuppressive activity. Arg1 inhibitor (nor-NOHA) and/or iNOS inhibitor [L-NG-Monomethylarginine, Acetate Salt (L-NMMA)] were added in PMN-MDSCs’ suppressive function assays.
-
FASEB J
Spatial Metabolism of Primary Limited Cutaneous Amyloidosis Based on Mass Spectrometry Imaging. [Abstract]2025 Sep 30;39(18):e71057. PMID: 40955599
nor-NOHA acetate purchased from MedChemExpress. Usage Cited in: FASEB J. 2025 Sep 30;39(18):e71057. [Abstract]
nonor-NOHA monoacetate (1, 10, 50, 100 μM) increased HaCaT cell viability.
nor-NOHA acetate purchased from MedChemExpress. Usage Cited in: FASEB J. 2025 Sep 30;39(18):e71057. [Abstract]
nonor-NOHA monoacetate (100 μM) increased K5 expression in HaCaT cells.
-
Clin Immunol
MAPK signaling pathway induced LOX-1+ polymorphonuclear myeloid-derived suppressor cells in biliary atresia. [Abstract]2024 Sep 3:110355. PMID: 39237078 -
Res Sq
Protective coinfection: influenza reprograms myeloid cells to limit CD8 T cell-mediated malaria pathology. [Abstract]2026 May 8:rs.3.rs-9404453. PMID: 42147182
溶剤 & 溶解度
H2O : 100 mg/mL (337.52 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (292 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Ng KP, et al. The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. PLoS One. 2018 Oct 11;13(10):e0205254. [Content Brief]
[2]. Jung C, et al. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res. 2010 Jan 1;85(1):147-54. [Content Brief]
[3]. Reid KM, et al. Liver I/R injury is improved by the arginase inhibitor, N(omega)-hydroxy-nor-L-arginine (nor-NOHA). Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G512-7. [Content Brief]
[4]. Chauhan , et al. Therapeutic Modulation of Arginase with nor-NOHA Alters Immune Responses in Experimental Mouse Models of Pulmonary Tuberculosis including in the Setting of Human Immunodeficiency Virus (HIV) Co-Infection. Trop Med Infect Dis. 2024 Jun 6;9(6):129. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 3.3752 mL | 16.8759 mL | 33.7519 mL | 84.3796 mL |
| 5 mM | 0.6750 mL | 3.3752 mL | 6.7504 mL | 16.8759 mL | |
| 10 mM | 0.3375 mL | 1.6876 mL | 3.3752 mL | 8.4380 mL | |
| 15 mM | 0.2250 mL | 1.1251 mL | 2.2501 mL | 5.6253 mL | |
| 20 mM | 0.1688 mL | 0.8438 mL | 1.6876 mL | 4.2190 mL | |
| 25 mM | 0.1350 mL | 0.6750 mL | 1.3501 mL | 3.3752 mL | |
| 30 mM | 0.1125 mL | 0.5625 mL | 1.1251 mL | 2.8127 mL | |
| 40 mM | 0.0844 mL | 0.4219 mL | 0.8438 mL | 2.1095 mL | |
| 50 mM | 0.0675 mL | 0.3375 mL | 0.6750 mL | 1.6876 mL | |
| 60 mM | 0.0563 mL | 0.2813 mL | 0.5625 mL | 1.4063 mL | |
| 80 mM | 0.0422 mL | 0.2109 mL | 0.4219 mL | 1.0547 mL | |
| 100 mM | 0.0338 mL | 0.1688 mL | 0.3375 mL | 0.8438 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
nor-NOHA acetate 関連分類
HY-112885A 関連分類
Powered by Bioz